Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triticum vulgare aqueous extract + polyhexanide is a topical combination product, often classified as a medical device, used for the management of acute and chronic skin lesions. The Triticum vulgare extract, specifically the Rigenase fraction obtained from germinated wheat plants, promotes wound healing by stimulating fibroblast activity, chemotaxis, and granulation tissue formation. It also exerts anti-inflammatory effects by reducing mediators such as IL-6, TNFα, and prostaglandin E2. Polyhexanide (PHMB) serves as a broad-spectrum antimicrobial agent that disrupts bacterial cell membranes, preventing infection in the wound bed. This combination is particularly utilized in the treatment of diabetic foot ulcers, venous leg ulcers, burns, and gynecological conditions such as vulvovaginitis and cervical ectropion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triticum vulgare aqueous extract + polyhexanide.